A supply crunch for Moderna marks an early stumble in the U.S. campaign to roll out updated booster shots to people ahead of a potential Covid-19 surge this fall and winter
Manufacturing-quality problem has led to some vaccine providers offering only the Pfizer-BioNTech booster shot
The FDA authorized newly modified Covid-19 boosters to target the latest versions of the Omicron variant. But, as WSJ’s Daniela Hernandez explains, a key part of the decision-making process was changed with these new shots. Photo: Laura Kammermannnew Covid-19 booster shot only from Pfizer Inc. and BioNTech SE , after a manufacturing-quality problem at a contract manufacturer caused a shortage of Moderna Inc.’s new booster shot.
In recent days, federal officials have advised state officials there is a limited supply of Moderna’s updated booster shots, said Marcus Plescia, chief medical officer of the Association of State and Territorial Health Officials.